Filing Flows › Foghorn Therapeutics (FHTX) › Q4 2024
Foghorn Therapeutics (FHTX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 6, 2025
Foghorn Therapeutics (FHTX) reported revenue of $2.9M for the fourth quarter 2024 (Q4 2024), -50% from a year earlier and -63% from the quarter before. Operating margin was -840.5%, net loss $19.5M (682.9% of revenue).
Foghorn Therapeutics, Q4 2024: revenue $2.9M (-50% year over year), operating margin -840.5%, net loss $19.5M, operating cash flow −$24.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.9M | -63% | -50% |
| Operating profit | −$24.0M | — | — |
| Net earnings | −$19.5M | — | — |
| Operating cash flow | −$24.5M | — | — |
What changed
Revenue was $2.9M in Q4 2024, down 50% year over year and down 63% from the previous quarter.
Operating costs exceeded revenue by $24.0M, an operating margin of -840.5%. Total costs fell 14% while revenue fell 50%. The quarter ended with a net loss of $19.5M, wider than the previous quarter's $19.1M loss. Non-operating items added $4.5M, -23% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$24.5M. Non-cash charges added back $761K of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $8.3M. Capital expenditures of $479K exceeded it, leaving free cash flow of −$25.0M.
Questions
What was Foghorn Therapeutics' revenue in the fourth quarter 2024?
Foghorn Therapeutics (FHTX) reported revenue of $2.9M for the fourth quarter 2024 (Q4 2024), -50% from a year earlier and -63% from the quarter before.
Was Foghorn Therapeutics profitable in the fourth quarter 2024?
Operating loss was $24.0M (-840.5% of revenue) and net loss $19.5M.